{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T05:52:11Z","timestamp":1668923531005},"reference-count":22,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.2176\/jns-nmc.2022-0228","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T22:12:29Z","timestamp":1668463949000},"page":"395-400","source":"Crossref","is-referenced-by-count":0,"title":["Epstein-barr Virus Negative Primary Central Nervous System Lymphoma Developed after Treatment of Glioblastoma: A Case Report"],"prefix":"10.2176","volume":"9","author":[{"given":"Novita Ikbar","family":"KHAIRUNNISA","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyuki","family":"YAMASAKI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwa Jeet","family":"AMATYA","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"TAKAYASU","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ushio","family":"YONEZAWA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"TAGUCHI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumpei","family":"ONISHI","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"HORIE","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>N Engl J Med<\/i> 352: 987-996, 2005","DOI":"10.1056\/NEJMoa043330"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kim JY, Jackman JG, Woodring S, et al.: Second primary cancers in long-term survivors of glioblastoma. <i>Neurooncol Pract<\/i> 6: 386-391, 2019","DOI":"10.1093\/nop\/npz001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Grommes C, Deangelis LM: Primary CNS lymphoma. <i>J Clin Oncol<\/i> 35: 2410-2418, 2017","DOI":"10.1200\/JCO.2017.72.7602"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Shao L, Xu C, Wu H, et al.: Recent progress on primary central nervous system lymphoma-from bench to bedside. <i>Front Oncol<\/i> 11: 689843, 2021","DOI":"10.3389\/fonc.2021.689843"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Van Ginderachter L, Cox T, Drijkoningen R, et al.: Non-hodgkin lymphoma after treatment with extended dosing temozolomide and radiotherapy for a glioblastoma: a case report. <i>Case Rep Oncol<\/i> 6: 45-49, 2013","DOI":"10.1159\/000346614"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sharma A, Gupta D, Mohanti BK, et al.: Non-hodgkin lymphoma following temozolomide. <i>Pediatr Blood Cancer<\/i> 53: 661-662, 2009","DOI":"10.1002\/pbc.22090"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zakaria Z, Fenton E, Khalil A, Sattar MT, Molnar P: Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma. <i>Br J Neurosurg<\/i> 28: 287-289, 2014","DOI":"10.3109\/02688697.2013.829554"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Evens AM, David KA, Helenowski I, et al.: Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. <i>J Clin Oncol<\/i> 28: 1038-1046, 2010","DOI":"10.1200\/JCO.2009.25.4961"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Evens AM, Choquet S, Kroll-Desrosiers AR, et al.: Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. <i>Am J Transplant<\/i> 13: 1512-1522, 2013","DOI":"10.1111\/ajt.12211"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice: Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. <i>Clin Transplant<\/i> 33: 1-22, 2019","DOI":"10.1111\/ctr.13652"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Tao K, Wang X, Tian X: Relapsed primary central nervous system lymphoma: current advances. <i>Front Oncol<\/i> 11: 649789, 2021","DOI":"10.3389\/fonc.2021.649789"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tabouret E, Houillier C, Martin-Duverneuil N, et al.: Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. <i>Neuro Oncol<\/i> 19: 422-429, 2017","DOI":"10.1093\/neuonc\/now238"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Gerson SL: Clinical relevance of MGMT in the treatment of cancer. <i>J Clin Oncol<\/i> 20: 2388-2399, 2002","DOI":"10.1200\/JCO.2002.06.110"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Park R, Amin M, Trikalinos NA: Temozolomide duration and secondary hematologic neoplasms: a literature review and implications for patients with neuroendocrine neoplasms. <i>J Neuroendocrinol<\/i> 34: e13178, 2022","DOI":"10.1111\/jne.13178"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Zhang Y, Chen S, Chen H, et al.: prognostic value and risk factors of treatment-related lymphopenia in malignant glioma patients treated with chemoradiotherapy: a systematic review and meta-analysis. <i>Front Neurol<\/i> 12: 1-12, 2022","DOI":"10.3389\/fneur.2021.726561"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Grossman SA, Ellsworth S, Campian J, et al.: Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors. <i>J Natl Compr Cancer Netw<\/i> 13: 1225-1231, 2015","DOI":"10.6004\/jnccn.2015.0151"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jang JE, Kim YR, Kim SJ, et al.: A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. <i>Eur J Cancer<\/i> 57: 127-135, 2016","DOI":"10.1016\/j.ejca.2016.01.016"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Li X, Li Y, Cao Y, et al.: Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database. <i>Int J Neurosci<\/i> 127: 1005-1011, 2017","DOI":"10.1080\/00207454.2017.1288624"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Glass J, Won M, Schultz CJ, et al.: Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. <i>J Clin Oncol<\/i> 34: 1620-1625, 2016","DOI":"10.1200\/JCO.2015.64.8634"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rubenstein JL, Hsi ED, Johnson JL, et al.: Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol<\/i> 31: 3061-3068, 2013","DOI":"10.1200\/JCO.2012.46.9957"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Omuro A, Chinot O, Taillandier L, et al.: Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematol<\/i> 2: e251-e259, 2015","DOI":"10.1016\/S2352-3026(15)00074-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Mishima K, Nishikawa R, Narita Y, et al.: Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C. <i>J Clin Oncol<\/i> 38: 2500, 2020","DOI":"10.1200\/JCO.2020.38.15_suppl.2500"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/9\/0\/9_2022-0228\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T04:58:28Z","timestamp":1668833908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/9\/0\/9_2022-0228\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":22,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2022-0228","relation":{},"ISSN":["2188-4226"],"issn-type":[{"value":"2188-4226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"article-number":"2022-0228"}}